BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17080719)

  • 1. Expression of cyclo-oxygenase-2 in ependymal tumors.
    Roma AA; Prayson RA
    Neuropathology; 2006 Oct; 26(5):422-8. PubMed ID: 17080719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclooxygenase-2 (cox-2) expression and angiogenesis in intracranial ependymomas.
    Onguru O; Kurt B; Gunhan O; Soylemezoglu F
    Clin Neuropathol; 2006; 25(5):216-20. PubMed ID: 17007443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
    Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
    Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry.
    Prayson RA
    Ann Diagn Pathol; 1999 Feb; 3(1):11-8. PubMed ID: 9990108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aurora B kinase expression in ependymal neoplasms.
    Gibson SE; Zeng WF; Weil RJ; Prayson RA
    Appl Immunohistochem Mol Morphol; 2008 May; 16(3):274-8. PubMed ID: 18301241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic use of D2-40 and annexin-1 in ependymal tumors].
    Wang YF; Piao YS; Lu DH; Chen L; Wang W; Yang H; Wei LF
    Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):595-8. PubMed ID: 22177242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subependymomas: clinicopathologic study of 14 tumors, including comparative MIB-1 immunohistochemical analysis with other ependymal neoplasms.
    Prayson RA; Suh JH
    Arch Pathol Lab Med; 1999 Apr; 123(4):306-9. PubMed ID: 10320142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical markers for prognosis of ependymal neoplasms.
    Korshunov A; Golanov A; Timirgaz V
    J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment.
    Witt H; Gramatzki D; Hentschel B; Pajtler KW; Felsberg J; Schackert G; Löffler M; Capper D; Sahm F; Sill M; von Deimling A; Kool M; Herrlinger U; Westphal M; Pietsch T; Reifenberger G; Pfister SM; Tonn JC; Weller M;
    Neuro Oncol; 2018 Nov; 20(12):1616-1624. PubMed ID: 30053291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity and specificity of epithelial membrane antigen staining patterns in ependymomas.
    Hasselblatt M; Paulus W
    Acta Neuropathol; 2003 Oct; 106(4):385-8. PubMed ID: 12898159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indications for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct from hSNF5/INI1.
    Kraus JA; de Millas W; Sörensen N; Herbold C; Schichor C; Tonn JC; Wiestler OD; von Deimling A; Pietsch T
    Acta Neuropathol; 2001 Jul; 102(1):69-74. PubMed ID: 11547953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas.
    Rushing EJ; Yashima K; Brown DF; White CL; Shay JW; Risser RC; Gazdar AF
    J Neuropathol Exp Neurol; 1997 Oct; 56(10):1142-6. PubMed ID: 9329458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic marker analysis in pediatric intracranial ependymomas.
    McLendon RE; Lipp E; Satterfield D; Ehinger M; Austin A; Fleming D; Perkinson K; Lefaivre M; Zagzag D; Wiener B; Gururangan S; Fuchs H; Friedman HS; Herndon JE; Healy P
    J Neurooncol; 2015 Apr; 122(2):255-61. PubMed ID: 25563815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of histopathological ependymoma variants.
    Neumann JE; Spohn M; Obrecht D; Mynarek M; Thomas C; Hasselblatt M; Dorostkar MM; Wefers AK; Frank S; Monoranu CM; Koch A; Witt H; Kool M; Pajtler KW; Rutkowski S; Glatzel M; Schüller U
    Acta Neuropathol; 2020 Feb; 139(2):305-318. PubMed ID: 31679042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antineuronal nuclei immunohistochemical staining patterns in childhood ependymomas.
    Parker JR; Armstrong DL; Strother D; Rudman DM; Dauser RC; Laurent JP; Deyd J; Rouah PE
    J Child Neurol; 2001 Aug; 16(8):548-52. PubMed ID: 11510923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
    Korshunov A; Golanov A; Timirgaz V
    J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spinal cord ependymomas and myxopapillary ependymomas in the first 2 decades of life: a clinicopathological and immunohistochemical characterization of 19 cases.
    Stephen JH; Sievert AJ; Madsen PJ; Judkins AR; Resnick AC; Storm PB; Rushing EJ; Santi M
    J Neurosurg Pediatr; 2012 Jun; 9(6):646-53. PubMed ID: 22656257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype.
    Suri VS; Tatke M; Singh D; Sharma A
    Indian J Cancer; 2004; 41(2):66-71. PubMed ID: 15318011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: a study of 41 cases.
    Prayson RA
    Am J Clin Pathol; 1998 Nov; 110(5):629-34. PubMed ID: 9802348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of protein 4.1 family members in ependymomas: a study of 84 cases.
    Rajaram V; Gutmann DH; Prasad SK; Mansur DB; Perry A
    Mod Pathol; 2005 Jul; 18(7):991-7. PubMed ID: 15731777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.